Damiano Rondelli

Academic Office:
840 S. Wood St, 
Suite 836 CSB, MC 713
Chicago, IL 60612

Phone: (312) 413-3547
Fax: (312) 413-4131


Clinical Office: 
1801 W. Taylor Street
Suite 1-E, OCC, MC 821
Chicago IL 60612
Phone: (312) 355-1625
Fax: (312) 355-1515

Clinic Hours:
Thursdays, 9:00 AM -5:00 PM 

Damiano Rondelli, MD

Michael Reese Professor of Hematology

Division Chief, Hematology/Oncology
Director of Blood & Marrow Transplant

Special Interests

Stem cell transplant, myeloproliferative neoplasms


Dr. Rondelli received his medical degree from the University of Bologna in Bologna, Italy and then completed his Residency and Fellowship in Hematology at the Institute of Hematology at the University of Bologna as well. He started his research on immunology of stem cell transplantation at the Fred Hutchinson Cancer Center in Seattle, WA. Before joining UIC, Dr. Rondelli served as an Assistant Professor at the Institute of Hematology and Medical Oncology at the University of Bologna.

Research Interests

Dr. Rondelli's lab research focuses on stem cell transplant immunology, with particular interest in in-vitro and in-vivo models of anti-CD34+ cell T cell alloreactivity.

Dr. Rondelli is actively involved in clinical research and is the Principal Investigator of investigator-inititiated Phase I and Phase II studies of allogeneic stem transplant for patients with high risk leukemia, lymphoma or myeloma, or for advanced myelofibrosis, or sickle cell anemia.

Selected Publications

  1. Araki H, Chute JP, Petro B, Halliday L, Hoffman R, Mahmud N. Bone marrow CD34+ cells expanded on human brain endothelial cells reconstitute lethally irradiated baboons in a variable manner. Leuk Lymphoma. 2010 Jun;51(6):1121-7. PMID: 20470216
  2. Nimmagadda S, Sweiss K, Mahmud N, Park Y, Rondelli D. Plerixafor given prior to the third leukapheresis to rescue an unsuccessful stem cell mobilization with cyclophosphamide and G-CSF. Bone Marrow Transplant. 2010;45:1121-2. 
  3. Patel P, Sweiss K, Shatavi S, Peace D, Clark N, Rondelli D. The impact of novel influenza A (H1N1) after hematopoietic SCT. Bone Marrow Transplant. 2010 Mar 15. [Epub ahead of print]
  4. Mahmud D, Nicolini B, van den Dries L,  Mahmud N, Rondelli D. Human CD4+CD25+ cells in combination with CD34+ cells and anti-thymocyte globulin to prevent anti-hematopoietic stem cell T cell alloreactivity. Biol Blood Marrow Transplant. 2011;1:61-8. PMID: 20708702
  5. Patel P, Sweiss K, Rondelli D. Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4). Bone Marrow Transplant. 2011;46:1326-30. PMID: 21132027
  6. Hacker ED, Larson J, Kujath A, Peace D, Rondelli D, Gaston L. Strength Training Following Hematopoietic Stem Cell Transplantation. Cancer Nurs. 2011 May-Jun;34(3):238-49. PMID: 21116175
  7. Sweiss K, Patel P, Rondelli D. Deferasirox increases Busulfan blood concentrations. Bone Marrow Transplant. Bone Marrow Transplant. 2012 Feb;47(2):315-6. PMID: 21460865 
  8. Saraf SL, Patel P, Ozer H, Peace DJ, Quigley JG, Mahmud N, Rondelli D. Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients. Bone Marrow Transplant. 2013 Feb;48(2):319-20. PMID: 22863727
  9. Patel P, Abbasian J, Mahmud N, Mahmud D, Horsthemke PM, Rondelli D. CD133+ hematopoietic progenitors show efficient allo-antigen presenting activity upon cross-talk with T cells. Bone Marrow Transplant. 2013 May;48(5):742-4. PMID: 23165492
  10. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. PMID: 24141007
  11. Gupta V, Gotlib J, Radich JP, Kröger NM, Rondelli D, Verstovsek S, Deeg HJ. JAK Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis. Biol Blood Marrow Transplant. 2014 Mar 27. pii: S1083-8791(14)00190-6. doi: 10.1016/j.bbmt.2014.03.017. [Epub ahead of print] Review.PMID: 24680977
  12. Rondelli, D, Goldberg, J. D, Marchioli, R, Isola, L, Shore, T. B, Prchal, J. T., Bacigalupo, A, Rambaldi, A., Klisovic, R. B., Gupta, V., Andreasson, B., Price, L. S., Scarano, M., Wetzler, M., Vannucchi, A. M., Najfeld, V., Barosi, G., Silverman, L. R, Hoffman, R. Results of Phase II clinical trial MPD-RC 101: Allogeneic hematopoeitic stem cell transplantation conditioned with fludarabine/melphalan in patients with myelofibrosis. Blood. 2014 Aug 14;124(7):1183-91. PMID: 24963042
  13. Huang X, Sun K, Zhao YD, Vogel SM, Song Y, Mahmud N, Zhao YY.Human CD34+ progenitor cells freshly isolated from umbilical cord blood attenuate inflammatory lung injury following LPS challenge. PLoS One. 2014 Feb 18;9(2):e88814. PMID: 24558433 Free PMC Article
  14. Mahmud N, Petro B, Baluchamy S, Li X, Taioli S, Lavelle D, Quigley JG, Suphangul M, Araki H.Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells. Biol Blood Marrow Transplant. 2014 Apr;20(4):480-9. PMID: 24374212
  15. Saraf S, Araki H, Petro B, Park Y, Taioli S, Yoshinaga KG, Koca E, Rondelli D, Mahmud N. Ex Vivo Expansion of Human Mobilized Peripheral Blood Stem Cells Using Epigenetic Modifiers. Transfusion. 2014 Nov 2. doi: 10.1111/trf.12904. [Epub ahead of print] PMID: 25363624
  16. Patel P,  A, Koshy M, Mahmud M, Oh A, Saraf SL, Quigley JG, Khan I, Sweiss K, Mahmud N, Peace DJ, DeMasi V, Weichselbaum  RR, Rondelli D. Linear accelerator-based total marrow irradiation (TMI) myeloablative fludarabine/ busulfan conditioning in allogeneic stem cell transplantation for high risk hematologic malignancies: a Phase I study. Biol Blood Marrow Transplant. 2014 Dec;20(12):2034-41 PMID: 25234438
  17. Mughal T, Tamari R, Rondelli D, Hasserjian R, Gupta V, Odenike T, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, and Hoffman R. Allogeneic Stem Cell Transplantation for Myelofibrosis: Reversing the chronic phase in the JAK inhibitors' era? Bone Marrow Transplant. 2015 Feb 9. doi: 10.1038/bmt.2014.323. [Epub ahead of print] PMID: 25665047
  18. Altman I, Lee IH, Burns MR, Rondelli D, Ennis WJ. Calcinosis Cutis Presenting in the Context of Long-Term Therapy for Chronic Myeloid Leukemia: A Case Report and Review of the Literature. WOUNDS. 2015;27(2):20-25.
  19. Oh A, Patel P, Sweiss K, Dudek S, Rondelli D.  Decreased Pulmonary Function in Asymptomatic Long Term Survivors after Busulfan-Based Myeloablative  Allogeneic Hematopoietic Stem Cell Transplant.  Bone Marrow Transplantation 2015 (in press)
  20. Kröger KM, Deeg J, Olavarria E, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Niederwieser D, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Passamonti F, Rondelli D, Barosi G. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN International Working Group. Leukemia 2015 (in press)
  21. Santosh L. Saraf, Annie Oh, Pritesh Patel, Karen Sweiss, Matthew Koshy, Sallie Campbell-Lee, Michel Gowhari, Johara Hassan, David Peace, John Quigley, Irum Khan, Robert Molokie, Lewis Hsu, Nadim Mahmud, Dennis Levinson, Joe G.N. Garcia, Victor R. Gordeuk, Damiano Rondelli. Alemtuzumab/Low dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD). Biol Blood Marrow Transplant 2015 (in press)